Curocell Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-38,239	-29,575
Depreciation & Amortization	6,335	4,706
Loss (Gain) From Sale of Assets	8.18	11.24
Stock-Based Compensation	1,522	1,410
Other Operating Activities	2,258	-1,590
Change in Other Net Operating Assets	-306.82	-226.61
Operating Cash Flow	-28,422	-25,264
Capital Expenditures	-441.02	-21,164
Sale of Property, Plant & Equipment	-	30.91
Sale (Purchase) of Intangibles	-768.92	-486.51
Investment in Securities	23,500	500
Other Investing Activities	20	-7.24
Investing Cash Flow	22,020	-21,127
Short-Term Debt Issued	-	1,000
Long-Term Debt Issued	-	46,899
Total Debt Issued	-	47,899
Short-Term Debt Repaid	-	-200
Long-Term Debt Repaid	-507.5	-30,201
Total Debt Repaid	-507.5	-30,401
Net Debt Issued (Repaid)	-507.5	17,497
Issuance of Common Stock	1,556	32,185
Other Financing Activities	-6.82	-
Financing Cash Flow	1,042	49,682
Foreign Exchange Rate Adjustments	23.53	-
Miscellaneous Cash Flow Adjustments	0	-0
Net Cash Flow	-5,337	3,291
Free Cash Flow	-28,863	-46,428
Free Cash Flow Per Share	-2065.13	-3923.04
Cash Interest Paid	1,921	1,401
Cash Income Tax Paid	22.26	38.48
Levered Free Cash Flow	-18,421	-
Unlevered Free Cash Flow	-16,794	-
Change in Net Working Capital	-702.18	-

Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.